151 related articles for article (PubMed ID: 498419)
1. In vitro and in vivo study of cross resistance between daunorubicin and daunorubicin-DNA complex in Ehrlich ascites tumor.
Skovsgaard T
Cancer Chemother Pharmacol; 1979; 2(1):43-7. PubMed ID: 498419
[TBL] [Abstract][Full Text] [Related]
2. Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo.
Skovsgaard T
Cancer Chemother Rep; 1975; 59(2 Pt 1):301-8. PubMed ID: 1149008
[TBL] [Abstract][Full Text] [Related]
3. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma.
Slater LM; Murray SL; Wetzel MW; Wisdom RM; DuVall EM
J Clin Invest; 1982 Nov; 70(5):1131-4. PubMed ID: 6182160
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells.
Skovsgaard T
Cancer Res; 1978 Dec; 38(12):4722-7. PubMed ID: 719649
[No Abstract] [Full Text] [Related]
5. Development of resistance to daunomycin (NSC-82151) in Ehrlich ascites tumor.
Dano K
Cancer Chemother Rep; 1971 Apr; 55(2):133-41. PubMed ID: 5118683
[No Abstract] [Full Text] [Related]
6. Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro.
Seeber S; Loth H; Crooke ST
J Cancer Res Clin Oncol; 1980; 98(2):109-18. PubMed ID: 6938517
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma.
Slater LM; Sweet P; Stupecky M; Wetzel MW; Gupta S
Br J Cancer; 1986 Aug; 54(2):235-8. PubMed ID: 3741759
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin.
Nielsen D; Eriksen J; Maare C; Jakobsen AH; Skovsgaard T
Br J Cancer; 1998 Nov; 78(9):1175-80. PubMed ID: 9820176
[TBL] [Abstract][Full Text] [Related]
9. Calcium modifies the accumulation and retention of daunorubicin by Ehrlich ascites carcinoma.
Murray SL; Du Vall EM; Slater LM
Cancer Chemother Pharmacol; 1984; 13(1):69-70. PubMed ID: 6733845
[TBL] [Abstract][Full Text] [Related]
10. Increased uptake of actinomycin D in Ehrlich ascites tumour cells induced by daunorubicin.
Lund-Andersen C; Skovsgaard T; Nissen NI
Cancer Chemother Pharmacol; 1983; 10(2):79-83. PubMed ID: 6831629
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of taurine uptake in multidrug resistant Ehrlich ascites tumor cells.
Poulsen KA; Litman T; Eriksen J; Mollerup J; Lambert IH
Amino Acids; 2002 Jun; 22(4):333-50. PubMed ID: 12107761
[TBL] [Abstract][Full Text] [Related]
12. Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129.
Meador J; Sweet P; Stupecky M; Wetzel M; Murray S; Gupta S; Slater L
Cancer Res; 1987 Dec; 47(23):6216-9. PubMed ID: 3677073
[TBL] [Abstract][Full Text] [Related]
13. Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor.
Skovsgaard T
Cancer Res; 1980 Apr; 40(4):1077-83. PubMed ID: 7357538
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study of the toxicity and antitumor activity of a DNA-rubomycin complex and free rubomycin].
Kim VKh; Smoryzanova OA; Riabchenko NI; Dedenkov AN
Antibiotiki; 1981 May; 26(5):361-5. PubMed ID: 7259142
[No Abstract] [Full Text] [Related]
15. Daunorubicin inhibition of DNA-dependent RNA polymerases from Ehrlich ascites tumor cells.
Barthelemy-Clavey V; Molinier C; Aubel-Sadron G; Maral R
Eur J Biochem; 1976 Oct; 69(1):23-33. PubMed ID: 991857
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells.
Skovsgaard T
Cancer Res; 1978 Jun; 38(6):1785-91. PubMed ID: 647687
[No Abstract] [Full Text] [Related]
17. Inhibition of DNA and RNA synthesis by daunorubicin in sensitive and resistant Ehrlich ascites tumor cells in vitro.
Dano K; Frederiksen S; Hellung-Larsen P
Cancer Res; 1972 Jun; 32(6):1307-14. PubMed ID: 5063994
[No Abstract] [Full Text] [Related]
18. Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide.
Nielsen D; Maare C; Eriksen J; Litman T; Friche E; Skovsgaard T
Biochem Pharmacol; 2000 Aug; 60(3):353-61. PubMed ID: 10856430
[TBL] [Abstract][Full Text] [Related]
19. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II.
Jensen PB; Jensen PS; Demant EJ; Friche E; Sørensen BS; Sehested M; Wassermann K; Vindeløv L; Westergaard O; Hansen HH
Cancer Res; 1991 Oct; 51(19):5093-9. PubMed ID: 1655244
[TBL] [Abstract][Full Text] [Related]
20. Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells.
Sehested M; Bindslev N; Demant EJ; Skovsgaard T; Jensen PB
Biochem Pharmacol; 1989 Sep; 38(18):3017-27. PubMed ID: 2571333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
